CD152 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

24 results for “CD152”

Trials

View all 15 →

CD155 in Bladder Cancer

151 participants · First posted Dec 28, 2018

CD155 Expression in Acute Myeloid Leukemia

93 participants · First posted Apr 17, 2024

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

24 participants · First posted Jun 6, 2005

Drugs

Investigational

Zalifrelimab

Anti-CD155 antibody-toxin conjugates(Biotecnol Ltd.)

CD154 gene therapy(University of California San Diego)

News

Biomarkers Identified for Camrelizumab-Apatinib Combination in Advanced Triple-Negative Breast Cancer

2D4 Monoclonal Antibody Shows Promise in Treating Systemic Lupus Erythematosus by Targeting CD132

Tasrif Pharmaceutical Secures Second U.S. Patent for CD155-Targeting Antibodies as Anti-TIGIT Field Contracts

Page 1 of 3